Source text for Eikon: Further company coverage: * Sees net profit for FY 2016 down 0 percent to 8 percent, or to be 259.1 million yuan to 281.6 million yuan * Bayer says Regorafenib from Bayer granted priority review in Japan for the second-line treatment of liver cancer Further company coverage: